Rifampicin as an adjunct to vancomycin therapy in MRSA septicaemia in burns

Burns

Volumn 25, Issue 7, 1999, Pages 640-644

  Gang, Raj Kumar ^b   Sanyal, Suhas C ^a   Mokaddas, Eiman ^a   Lari, Abdul Reda ^b  

^a IBN SINA HOSPITAL   (Kuwait)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; VANCOMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BURN; BURN INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; SEPTICEMIA; SKIN GRAFT; WOUND INFECTION;

ADOLESCENT; ADULT; BACTEREMIA; BURN UNITS; BURNS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; KUWAIT; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; SURVIVAL RATE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 0033231916     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(99)00045-5     Document Type: Article

References (25)

1. Bang R.L., Gang R.K., Sanyal S.C., Mokaddas E., Ebrahim M.K. Burn septicaemia: an analysis of 79 patients. Burns. 24:1998;354-361.
2. Taylor G.D., Kibsey P., Kirkland T., Buroughs E., Tredget E. Predominance of staphylococcal organisms in infections occurring in a burn intensive care unit. Burns. 8:1992;32-35.
3. Mokaddas E.M., Mustafa A.S., Sanyal S.C. The prevalence, antibiotic and plasmid profiles of methicillin resistant Staphylococcus aureus (MRSA) in the burns unit of a Kuwaiti hospital. The Journal of the Kuwait Medical Association. 28:1996;435-439.
4. Coello R., Jimenez J., Garacia M., et al. Prospective study of infection, colonization and carriage of methicillin resistant Staphylococcus aureus in an outbreak affecting 990 patients. Euro J Clin Microbiol Infec Dis. 13:1994;50-55.
5. Faoagali J.L., Thong M.L., Grant D. Ten years experience with methicillin resistant Staphylococcus aureus in a large Australian hospital. J Hosp Infect. 20:1992;13-19.
6. Lesseva M.I., Hadjiiski O.G. Staphylococcal infections in the Sofia Burn Centre. Bulgaria Burns. 22:1996;279-282.
7. Cafferkey M.T. The treatment of invasive MRSA infections. Cafferkey M.T., Methicillin resistant Staphylococcus aureus: clinical management and laboratory aspects. 1992;125-148 Marcel Dekker Inc.
8. Kloos W.E., Lambe S.W. Jr. Staphylococcus. Balows A., Hausler W.J., Herrmann K.L., Lsenberg H.D., Shadomy H.J., Manual of clinical Microbiology. 5th ed. 1991;222-237 ASM, Washington, DC.
9. Archer G.L., Tenenbaum M.J., Haywood H.B. III. Rifampicin therapy of Staphylococcus epidermidis: use in infections from indwelling artificial devices. JAMA. 240:1978;751-753.
10. Hackbarth C.J., Chambers H.F., Sande M.A. Serum bactericidal activity of rifampicin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 29:1986;611-613.
11. Bahl D, Miller DA, Leviton I, Gialanella P, Wollin MJ, Liu W, Perkins R, Miller MH. In vitro activities of ciprofloxacin and rifampicin alone and in combination against growing and nongrowing strains of methicillin susceptible and methicillin resistant staphylococcus aureus. Antimicrob Agents Chemother 1997;1293-1297.
12. Tan T.Q., Mason E.O. Jr, Ou C.N., Kaplan S.L. Use of intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. Antimicrob Agents Chemother. 37:1993;2401-2406.
13. Faville R.J. Jr, Zasske D.E., Kaplan E.L., et al. Staphylococcus aureus endocarditis: combined therapy with vancomycin and rifampicin. JAMA. 240:1978;1963-1965.
14. National Committee for Clinical Laboratory Standards . Antimicrobial disc susceptibility tests. Approved Standards. 1993;. (M2-15 NCCLS).
15. Rifamycins. Lambert H.P., O'Grady F.W., Antibiotic and chemotherapy. 6th ed. 1992;263-267 Churchill Livingstone.
16. Gopal V., Bisno A.L., Silverblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis: in vivo and in vitro observations. JAMA. 236:1976;1604-1606.
17. Watanakunakorn C., Guerricro J.C. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother. 19:1981;1089-1091.
18. Kaye D. The clinical significance of tolerance of Staphylococcus aureus. Ann Int Med. 93:1980;924-926.
19. Rybak M.J., Albrecht L.M., et al., Berman J.R., et al. Vancomycin pharmacokinctics in burns patients and intravenous drug abusers. Antimicrob Agents Chemother. 34:1990;792-795.
20. Palmer S.M., Rybak M.J. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampicin, against Staphylococcus aureus in an in vitro model with infected platelet fibrin clots. Antimicrob Agents Chemother. 40:1996;701-705.
21. Mandel G.L., Sande M.A. Drugs used in the chemotherapy of tuberculosis and leprosy. Gilman A.G., Rall T.W., Neis A.S., Taylor P., The pharmacological basis of therapeutics. 1998;1149-1152 Pergamon Press, Inc, New York.
22. Mandel G.L., Vest T.K. Killing of intraleukocytic Staphylococcus aureus by rifampicin: in vitro and in vivo studies. J Infect Dis. 125:1972;486-490.
23. Ein M.E., Smith N.J., et al., Aruffo J.S., et al. Susceptibility and synergy studies of methicillin resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 16:1979;655-659.
24. Lourg F.D., Chang D.S., Lash P.R. Surgery of combination of vancomycin, gentamycin and rifampicin against methicillin-resistant coagulase negative staphylococci. Antimicrob Agents Chemother. 23:1983;932-934.
25. Tauzon C.U., Lin M.Y.C., Sheagren J.N. In Vitro activity of rifampicin alone and in combination with naficillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother. 13:1978;759-761.